While Finland agreed to pay out in 2011, the U.K. was still knocking back claimants in 2012. Now, though, the U.K. government is reportedly readying to pay 60 people $1.7 million each.
Theravance, the biotech engine behind GlaxoSmithKline's bright future in COPD, is gearing up to split in two next quarter, with one publicly traded company handling its revenue-generating drugs and the other leading the charge on R&D.
The earnings reports for the biggest of Big Pharma are all in. Bayer reported last week, making it possible to see how they stacked up as they came into the new year. There are no big surprises....
Galapagos NV's collaboration with GlaxoSmithKline has hit a roadblock. Late last week the Belgian biotech reported that its Big Pharma partner had hit the brakes on a Phase II study of GSK2586184 for lupus after a first look at the data failed to demonstrate a positive effect.
It remains to be seen how much GlaxoSmithKline's China bribery scandal will cost the British pharma, but it has already cost CEO Andrew Witty up to $410,000 in potential bonus money, according to the company's annual report.
When GlaxoSmithKline launched respiratory med Breo, media reports buzzed over the company's emphasis on the treatment's risks. But as GSK spokesman Juan Carlos Molina told FiercePharmaMarketing, hammering home risks--as well as benefits--is not necessarily something new for Glaxo.
European regulatory authorities gave Teva a positive opinion for its DuoResp Spiromax inhalation powder, designed to treat asthma and chronic obstructive pulmonary disease. With the recommendation from the Committee for Medicinal Products for Human Use, Teva hopes to have final approval within a few months.
A European Medicines Agency committee has recommended approval for another COPD treatment from GlaxoSmithKline, setting the stage for a likely nod in the coming months as the drugmaker looks to bolster its respiratory franchise.
China has yet to leverage any formal penalties on GlaxoSmithKline for the $489 million bribery scandal that broke there last summer. But punishment may be on the way from GSK's home base.
While it's still unclear how long copycats will take to make a serious dent in GlaxoSmithKline's respiratory franchise once generic competition inevitably erodes sales of the $8.8 billion-selling Advair, Glaxo may soon have a new building block with European regulators' new recommendation for combo med Anoro.